| Literature DB >> 33795007 |
K Morikane1, P L Russo2, K Y Lee3, M Chakravarthy4, M L Ling5, E Saguil6, M Spencer7, W Danker8, A Seno9, E Edmiston Charles10.
Abstract
INTRODUCTION: Surgical site infections (SSIs) are a significant source of morbidity and mortality in the Asia-Pacific region (APAC), adversely impacting patient quality of life, fiscal productivity and placing a major economic burden on the country's healthcare system. This commentary reports the findings of a two-day meeting that was held in Singapore on July 30-31, 2019, where a series of consensus recommendations were developed by an expert panel composed of infection control, surgical and quality experts from APAC nations in an effort to develop an evidence-based pathway to improving surgical patient outcomes in APAC.Entities:
Keywords: Asia–Pacific; Guidelines; Healthcare-associated infection; Implementation; Surgical site infection
Mesh:
Year: 2021 PMID: 33795007 PMCID: PMC8017777 DOI: 10.1186/s13756-021-00916-9
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Expert panel key recommendations for guideline selection, adaptation and dissemination
| Guideline selection, adaptation and dissemination—expert recommendations |
|---|
| 1. Systems and governance for SSI prevention and surveillance within APAC should be consistent with global and/or national guidelines. Guidelines should be implemented at both the national and individual hospital level |
| 2. Professional societies within respective countries may also formulate their own guidelines using frameworks provided by global guidelines and should be consistent with their national guidelines. National guidelines should be situationally applicable and adaptable to an institution’s cultural, socioeconomic, clinical, health economic and political context [ |
| 3. Where possible, local systems and processes for SSI prevention and surveillance should be developed and standardised based on local evidence to ensure contextual relevance and long-term sustainability |
| 4. Guidelines should be actively disseminated to stakeholders who are in a position to make impactful changes |
| 5. Guidelines should be ‘living documents’, updated on an ongoing basis as new evidence is accumulated |
Fig. 1Multimodal SSI prevention and control improvement strategy. Expert panel assessment of multimodal SSI prevention and control improvement strategy.
Adapted from: World Health Organization. Implementation manual to support the prevention of surgical site infections at the facility level—turning recommendations into practice (interim version) [13]
Evidence-based care bundle elements.
Adapted from lecture “A Speciality or Global Approach to SSI Prevention: Clean, Clean-Contaminated and Contaminated Procedures” delivered by Dr Charles E Edmiston, Jr., at the APAC Surgical Site Infection Prevention Symposium (Singapore, 31 July 2019)
| Bundle elements | Classa | Mechanistic benefits |
|---|---|---|
| Normothermia | 1A | Less bleeding/preserve immune function in wound bed/enhanced wound healing |
| Perioperative | 1A | Tissue antisepsis/intraoperative conc > MIC [ |
| Glycaemic control | 1A | Preserve granulocytic immune function/enhance wound healing |
| Antimicrobial (triclosan) coated sutures (fascia/subcuticular closure) | 1A | Mitigate nidus of infection/local tissue antisepsis |
| Preadmission CHG showering/bathing | 1B | Skin antisepsis/reduce skin bioburden |
| Perioperative skin prep with 2% CHG/70% alcohol | 1A | Skin antisepsis/reduce skin bioburden |
| Separate wound closure tray | II | Mitigate instrument contamination |
| Glove change prior to fascia/subcuticular closure | II | Disrupt cross-contamination across tissue planes |
| Supplemental oxygen (colorectal surgery) | 1A | Enhanced tissue oxygenation and immune function/ metabolic benefits/wound healing |
| Oral antibiotics/mechanical bowel prep (colorectal surgery) | 1A | Reduce bioburden within the bowel lumen and on brush border surfaces |
| Wound edge protector (colorectal, vascular and OB/GYN surgeries) | 1B | Intraoperative wound antisepsis/minimising wound contamination |
| Staphylococcal decolonization (orthopaedic and CT surgeries) | 1A | Mitigate |
| Smoking cessation (orthopaedic, neurological, CT, and likely all surgeries) | 1B | Preserve angiogenesis/reduce risk of dehiscence/enhance wound healing |
| Intraoperative irrigation of the surgical wound with 0.05% CHG | II | Mitigate wound contamination prior to closure |
| OR traffic control – minimize door openings | No recommendation/unresolved | Reduce OR air bioburden |
CHG, chlorhexidine gluconate; CT, cardiothoracic; MRSA, methicillin-resistant Staphylococcus aureus; OB/GYN, obstetrics/gynaecology; OR, operating room, conc > MIC [90], concentration greater than the minimal inhibitory concentration required to inhibit the growth of 90% of surgical wound pathogens
aColumn 2: Interventional evidence-based criteria derived from “CDC SSI Guidelines Evidence-Based Criteria documentation and Wisconsin Division of Public Health Service Supplemental Guidance for the Prevention of Surgical Site Infections: An Evidence-based Perspective [60–62]. CDC categories: 1A = strong recommendation supported by high to moderate–quality evidence suggesting net clinical benefits or harms; 1B = strong recommendation supported by low-quality evidence suggesting net clinical benefits or harms or an accepted practice (eg, aseptic technique) supported by low to very low–quality evidence; 1C = A strong recommendation required by state or federal regulation; Category II = weak recommendation supported by any quality evidence suggesting a trade-off between clinical benefits and harms; No recommendation/unresolved issue = An issue for which there is low to very low–quality evidence with uncertain trade-offs between the benefits and harms or no published evidence on outcomes deemed critical to weighing the risks and benefits of a given intervention